This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Rheumatology, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Michelle Petri, MD, MPH; Robert Brodsky, MD

JAMA. 2006;295:559-560.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Systemic lupus erythematosus is a devastating systemic autoimmune disease that predominantly affects young women, is more common in African-Americans than in whites, and results in poor quality of life. Lupus has no cure, and up to 90% of patients require corticosteroids for disease control.¹ More than half of patients with lupus have permanent organ damage, much of which is either directly due to or increased by corticosteroids.¹ Mortality is increased in patients with systemic lupus erythematosus, with accelerated atherosclerosis the most important contributing factor,² although the risk of cancer is also increased.³

There have been no new US Food and Drug Administration-approved drugs or biologic treatments for systemic lupus erythematosus in many decades. The criterion standard treatment for severe organ-threatening lupus (renal lupus, central nervous system lupus) is monthly intravenous cyclophosphamide (500–1000 mg/m²) for a 6-month induction period, followed by quarterly intravenous . . . [Full Text of this Article]

Author Affiliations: Johns Hopkins University School of Medicine, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus
Richard K. Burt, Ann Traynor, Laisvyde Statkute, Walter G. Barr, Robert Rosa, James Schroeder, Larissa Verda, Nela Krosnjar, Kathleen Quigley, Kimberly Yaung, Marcello Villa, BS, Miyuki Takahashi, Borko Jovanovic, and Yu Oyama
JAMA. 2006;295(5):527-535.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures
Dussan et al.
Lupus 2008;17:1079-1085.
ABSTRACT